“Smart investors will look for biotech stocks that have drug pipelines full of good prospects, as well as balance sheets strong enough to withstand any… Read More »Strong Drug Pipelines (And Balance Sheets) May Make These The Best Biotech Stocks To Buy Right Now
“This year didn’t start out with a bang for these two biotechs, but their performances over the past few months have been breathtaking,” observes the… Read More »Having Posted Tremendous Gains In Recent Months, Are Either Of These 2 Small-Cap Biotech Stocks Buys?
When it comes to the question of which biotech companies could be the next M&A targets, one analyst cited in today’s article says the “easy… Read More »The Next Biotechs To Be Bought Up
Investors looking for a post-election idea may want to consider the ETF highlighted in today’s article, which tracks an index “comprised of small- and mid-cap… Read More »Market History Suggests This “Breakthrough” ETF Is A Smart Post-Election Idea
Today’s article highlights a plethora of new stocks to watch in the biotech, tech, cleantech, psychedelics and cannabis spaces, among others. In regards to the… Read More »New Stocks To Watch In Biotech, Cleantech, Psychedelics & More
The author of today’s article notes that, while the “upside in biotech sector has been led by positive developments at small companies, primarily the ones… Read More »4 ‘Strong Buy’/‘Buy’ Biotech Stocks
“With the number of new drugs and biologics going up day by day, there has never been a better time to invest in biotech stocks,”… Read More »3 Top Stock Picks From The Outperforming Biotech Sector
“With companies like Pfizer (NYSE:PFE) giving possible hope for an end of year vaccine and a recent gap up in IBB (Nasdaq Biotechnology ETF), now… Read More »Newer Biotech Issues To Watch
Despite biotech’s outperformance year-to-date, the authors of today’s article still see the industry as attractive – and they outline three key strategic themes driving their… Read More »The Investment Thesis For Biotech (And Especially Biopharma)
After an initial analysis of clinical data back in May failed to demonstrate a statistically significant impact on the biomarkers associated with the disease, a… Read More »This Buy-Rated Biotech With An Effective Alzheimer’s Drug Has Upside Potential Of Over 100%